Dr. Adeyemi Johnson

Medical Director & Chief Executive Officer, First Cardiology Consultants

Conference Speaker

Dr. Johnson completed medical school at the University of Lagos Medical School, Nigeria in 1980. Between 1983 and 1984, he studied Public Health and Preventive Medicine at Yale University School of Medicine, New Haven, Connecticut, USA. Between 1984 and 1990, Dr. Johnson completed his training in Internal Medicine and held a Cardiology Fellowship at the College of Physicians & Surgeons of Columbia University, New York, USA. Over the next year, Dr. Johnson held an Interventional Cardiology Fellowship at the Loma Linda University Medical Center, Loma Linda, California, USA.

He became the Director of Echocardiography & Stress Echo Lab at the Lancaster Community Hospital, Lancaster, California, USA, and was later appointed the Director of Critical Care Unit, Palmdale Hospital, Palmdale, California, USA. He has also worked within the Pharmaceutical Industry as Faculty on the Peripheral Vascular Preceptorship Programs of Abbott Corporation and Spectranetics Corporation.

With an excess of 25 years’ experience as a cardiologist, Dr. Johnson is highly regarded as an expert in Interventional Cardiology. Within this specialist field, previous positions held by him include Interventional Cardiologist, Director of Vascular Interventional Cardiology, and Director of the Non-Invasive Diagnostic Vascular Laboratory all at the Mid Carolina Cardiology/Presbyterian Hospital Charlotte, North Carolina, USA. Held since 2006, he is currently an Associate Professor at Wake Forest University Medical Center, Winston Salem, North Carolina, USA. He is the Medical Director at First Cardiology Consultants, Lagos, Nigeria.

Dr. Johnson’s research interests include cardiac imaging; coronary stenting; clinical trials of cardiovascular drugs; myocardial infarction; and coronary artery disease. As a seasoned clinician scientist, Dr. Johnson has been principal and co-investigator on over 80 major studies such as: EPILOG – A Multicenter, Randomized Trial Evaluating 30-Day and 6-month Clinical Outcome with Three Different Treatment Strategies in Patients Undergoing Percutaneous Coronary Intervention. CADILLAC – A Randomized Comparison of the ACS RX Multi-Link Coronary Stent System with or without Abciximab verses PTCA with or without Abciximab in the Treatment of Patients with Myocardial Infarction. VALIANT (VALsartan In Acute myocardial iNfarcTion) Multinational, multicenter, double-blind, randomized active controlled, parallel group study comparing the efficacy and safety of long-term treatment with valsartan, captopril and their combination in high-risk patients after myocardial infarction. MIST – A Prospective, Randomized, Multi-Center Parallel-Group Comparison of the OTW Megalink? SDS Peripheral Stent System Versus the Boston Scientific Wallstent? Iliac Endoprosthesis in the Treatment of De Novo or Restenotic Iliac Artery Stenoses for the Treatment of Sub-optimal Post-procedural Percutaneous Transluminal Angioplasty (PTA) results.

He is a member of various distinguished medical societies including the American Heart Association, American College of Cardiology, American Medical Association, North Carolina Medical Society, Mecklenburg County Medical Society, and the International Society of Endovascular Surgery. He is also a Fellow of both the American College of Cardiology, and the American College of Chest Physicians.

In July 2009, Dr. Johnson made history by performing the first Cardiac Catheterization, Coronary Angiogram in Nigeria. He is currently the director of the critical care unit at First Cardiology and has been involved in critical care medicine for over 30 years.